An uncommon case of lymphoplasmacytic lymphoma in cerebellopontine angle region
Case report with a literature review
Chengrui Yan, MD, Xiangyi Kong, MD, Lanshu Yang, MD, Wenbin Ma, MD

Abstract
In the central nervous system, cerebellopontine angle (CPA) lymphomas are rare; few cases have been reported. Lymphoplasmacytic lymphoma (LPL) in the CPA is rarer still, and often misdiagnosed as acoustic neuroma.
We report a rare case of CPA LPL—a challenging diagnosis guided by clinical presentations, radiological signs, and postoperative pathological test.
A 43-year-old woman presented with headaches. Her magnetic resonance imaging revealed an abnormal homogeneously enhancing mass in the left CPA. We present detailed analysis of her disease and review relevant literature.
When surgically treated, her specimen showed a typical LPL histopathology pattern. After surgery, the patient’s symptoms improved greatly, and she received chemotherapy.
Despite its rarity, LPL should be considered in differential diagnoses of CPA lesions that mimic acoustic neuromas.

Abbreviations: CNS = central nervous system, CPA = cerebellopontine angle, GFAP = glial fibrillary acidic protein, LPL = lymphoplasmacytic lymphoma, MRI = magnetic resonance imaging, NSE = neuron-specific enolase, PCNSLs = primary central nervous system lymphomas, Syn = synaptophysin, T1WI = T1-weighted image, T2WI = T2-weighted image, WM = Waldenström macroglobulinemia.

Keywords: cerebellopontine angle region, differential diagnosis, lymphoplasmacytic lymphoma

1. Introduction
Primary central nervous system (CNS) lymphoma is a very rare aggressive non-Hodgkin disease that originates in CNS (brain, leptomeninges, spinal cord, or eyes) without evident involvement of other systemic locations. They account for less than 1% of all intracranial tumors but have apparently increased over the last 2 decades in both immunocompromised and immunocompetent patients.[1] They may be solitary or multiple, with a predilection for the corpus callosum, basal ganglia, thalami, and paraventricular region.[1] Cerebellopontine angle (CPA) lymphomas are rare and only a handful of cases have been reported so far. Lymphoplasmacytic (or lymphoplasmacytoid) lymphoma (LPL) is an uncommon mature B-cell lymphoma that usually involves the bone marrow and, less commonly, the lymph nodes and spleen.[2] LPLs in the CNS are uncommon, and rarer still in the CPA.
Here, we report an uncommon solitary primary LPL in the CPA, and discuss its treatment and differential diagnoses. Although a few CPA lymphomas have been reported previously, this is the first reported case of a CPA LPL, to our knowledge.

1.1. Case presentation
A 43-year-old woman was admitted to our hospital complaining of continuous frontal and occipital headaches for 4 months, and a left hearing loss for 2 months. One week before admission, she began vomiting for about 5 times a day. She had no significant medical background or family history. No lymphadenopathy or organomegaly were found upon general physical examination. Skull, bone, cardiac, chest, and per rectal examinations revealed no abnormalities. She was oriented and conscious. Visual fields and acuity was normal. Neurological examinations revealed normal motor function and sensation in all four limbs. No obvious changes in superficial or deep tendon reflexes were detected. Ataxia and pathological signs were absent. Routine hematological test results were all normal and the serological HIV test was negative. However, a brain magnetic resonance imaging (MRI) showed a homogeneously enhancing mass in the
left CPA, measuring $5 \text{ cm} \times 5 \text{ cm} \times 3.5 \text{ cm}$; neuritis or a CPA tumor was suspected (Fig. 1). The tumor showed relatively equal signal intensities on T2-weighted imaging (T2WI) and T1-weighted imaging (T1WI), extending slightly to the left temporal pole meninges. The mass also mildly compressed the cerebellum, the adjacent brain stem, the aqueduct of Sylvius, and the fourth ventricle. The MRI revealed cerebellar swelling, dilation of supratentorial ventricles system, and interstitial edema. Along with her clinical history, these findings implied an acoustic neuroma in the left side.

The patient underwent a left retromastoid craniectomy and a tumor resection. During surgery, a well-defined left CPA lesion extending to the left internal auditory canal was seen. It was against the petrous bone and tentorium cerebelli, with abundant vascularization and relatively clear boundaries. The tumor was extirpated as multiple pieces of friable, gray, and firm tissues, which were fixed in 10% paraformaldehyde and embedded in paraffin. Microscopically, the tissues were a mixture of cancerous lymphocytes and plasma cells. Immunohistochemical tests showed the tissues to be positive for CD38, CD20, CD38, and CD79a, and negative for AE1/AE3, Bcl-6, CD3, CD10, glial fibrillary acidic protein, neuron-specific enolase, and Syn. The positive rate for Ki-67 was 10%.

Pathological examination confirmed the diagnosis of LPL (Fig. 2). The patient then underwent a bone marrow biopsy and a computed tomography (CT) scan of the entire chest, abdomen, and pelvis. No abnormalities were found. According to the Ann Arbor–Cotswald staging system for lymphomas, this case of CPA LPL was classified as Stage I, indicating that the cancer was located in a single region.

One week after the surgery, the patient’s headache and hearing loss were much relieved. Postoperative MRI showed that the CPA...
tumor was totally removed, and adjacent structures were thoroughly decompressed. She was then transferred to the hematology department for chemotherapy. The chemotherapy protocol was the cyclophosphamide, vincristine, and prednisone regimen along with rituximab. After 6 cycles of chemotherapy, her Karnofsky Performance Scale score was 95. An MRI performed half a year after the surgery showed no recurrence (Fig. 3).

2. Discussion
A few rare tumors can occur in the CPA. After excluding cranial nerve schwannomas (1.4%), cholesteatoma (2.4%), meningioma (3.1%), and acoustic neuromas (91.3%) from a series of 1354 CPA tumors, 25 uncommon tumors remained, including lipomas, metastatic tumors, gliomas, hemangiomas, hemangio-blastomas, arachnoid cysts, dermoids, and a teratoma.[3] In a series of 32 nonacoustic CPA tumors, hemangiosarcoma was also recorded.[3]

Primary central nervous system lymphomas (PCNSLs) are uncommon tumors that account for approximately 0.8% of lymphomas at all sites and 0.3% to 1.5% of all intracranial tumors.[4] They may occur in both immunocompromised and immunocompetent individuals.[4] For immunocompetent patients, the mean age at diagnosis of PCNSL is 55 years; for AIDS patients, the mean age is 31 years. The female: male ratio is 2:3. PCNSLs often occur in thalami, periventricular region, corpus callosum, and basal ganglia.[10] However, only 15 cases of PCNSLs at the CPA have been reported in the literature.[6] Almost all PCNSLs are aggressive neoplasms of diffuse large B-cell lymphoma type; low-grade malignant lymphomas such as peripheral T-cell, Burkitt lymphoma, marginal mantle cell lymphoma, and LPL are rare.[7]

LPL is a kind of non-Hodgkin lymphoma with low-grade malignancy, and composed of plasma cells, plasmacytoid lymphocytes, and small B cells. Its incidence is approximately 3% to 4.5% per year worldwide.[8] Most patients demonstrate increased monoclonal serum IgM, and a few have elevated IgA or IgG.[9] LPL usually involves the bone marrow and, less commonly, the spleen and lymph nodes. The 2008 World Health Organization (WHO) classification defined Waldenström macroglobulinemia (WM) as a clinicopathologic entity associated with an IgM monoclonal gammapathy and marrow involvement, which is the commonest manifestation of LPL.[10] The pathogenesis of LPL is incompletely understood. However, deletions of 6q21 have been identified as a common site of chromosome loss in patients with WM.[11] These findings suggest that MYD88 mutations that lead to the activation of NF-kB family transcription factors are pivotal role in the pathogenesis of LPL.[2,12] Chronic infection with HIV and hepatitis C virus (HCV) has also been implicated as risk factors.

To our knowledge, only 24 cases of primary CNS LPL have been reported previously[13-16] of which 9 as well as the present one included detailed information (Table 1). Our case is the first reported case of LPL originating in the CPA.

The average onset age of primary CNS LPL is 43.3 years, and a high proportion of patients are young or middle-aged (Table 1). The brain parenchyma and meninges are the most commonly involved sites. Occupying lesions are most commonly found through head MRIs.[9] Clinical presentations of patients with CNS LPL vary; the most common but atypical features include focal symptoms and intracranial hypertension; however, typical WM presentations such as infiltration of other organs and gammapathy are rare.[17] Solitary CPA lymphoma must be distinguished from acoustic neurilemmomas, arachnoid cysts, paraganglioma of the glomus jugulare, lipomas, hemangiomas, angiolastoma, choroid plexus papillomas, teratoma, craniopharyngioma, glio- mas, liposarcoma, chondrosarcoma, medulloblastoma, metastatic tumors, primary epidermoid carcinomas, endodermal sinus tumors, and malignant schwannoma with rhabdomyoblastic differentiation. Signs, symptoms, and tests—especially imaging examinations—of some common differential diagnoses are listed in Table 2. Surgical intervention, including a biopsy for a pathological diagnosis, is highly recommended. Some studies have also indicated that 13.3% to 16% patients had a positive result from cerebrospinal fluid cytological examinations.[17] The CPA LPL immunophenotype is sometimes similar to other small B-cell lymphoid neoplasms, such as marginal mental cell lymphoma; thus, testing for serum immunoglobulin and gene mutation can be useful.

The predominant treatments for primary CNS LPL are surgery, radiotherapy, chemotherapy, and molecular targeted therapy.[16]
As the cases are few, no specialized guideline has yet been developed. The chemotherapy regimen is CHOP or cyclophosphamide, vincristine, and prednisone, with rituximab—a monoclonal antibody widely used against B cell lymphoma. Patients who received rituximab along with CHOP reportedly had significantly higher rates of overall response than patients who only received the traditional regimen. The positive rate of Ki-67 in LPL is generally less than 20% (~10% in our case), which leads to a benign prognosis. For asymptomatic patients, regular follow-up alone is recom-

**Table 1**
Clinical features of the reported cases of primary CNS LPL.

| No. | Sources       | Age (y/gender) | Symptoms                          | Examinations            | Lesion location                  | Surgery                        | Radiotherapy/chemotherapy | Outcome                  |
|-----|---------------|----------------|-----------------------------------|------------------------|---------------------------------|--------------------------------|---------------------------|--------------------------|
| 1   | Gaudin et al  | 53/F           | Headache, blurry vision           | Head MRI, PET-CT       | Left parietal lobe              | Tumor resection                | Radiotherapy             | 1-year follow-up with no recurrence |
| 2   | Ikeda et al   | 43/F           | Visual acuity, vision defect      | Head MRI               | Optic chiasm, right hypotalamus, internal capsule, lateral ventricle surroundings | T4 spinal cord               | Chemotherapy             | 51 mo follow-up with no recurrence |
| 3   | Lim et al     | 50/M           | —                                 | —                      | Tumor resection                 | Chemotherapy                   | —                         | —                        |
| 4   | Lim et al     | 38/M           | —                                 | —                      | Lesion biopsy                   | Chemotherapy                   | —                         | 2.6 mo follow-up in the treatment |
| 5   | Hong et al    | 50/F           | —                                 | —                      | Epidural lesion                 | Chemotherapy                   | —                         | 8 mo follow-up in the treatment |
| 6   | Hong et al    | 21/M           | —                                 | —                      | Intra spinal lesion             | Chemotherapy                   | —                         | 5 mo follow-up in the treatment |
| 7   | Yuan et al    | 35/M           | Instability, dizziness            | Head CT, Head MRI      | Epencephalon                    | Tumor resection                | —                         | —                        |
| 8   | Carrasco et al| 40/F           | Hypopituitarism                   | Head MRI               | Suprasellar region              | Tumor resection                | —                         | 4 y follow-up with no recurrence |
| 9   | Braks et al   | 42/F           | Headache, vertigo, epilepsy       | Head MRI/MRS           | Right centrum semiovale         | Lesion biopsy                  | Chemotherapy, intrathecal injection | 6 mo follow-up with no recurrence |
| 10  | Our case      | 43/F           | Headache, hearing loss, recurrent vomiting | Head MRI               | Left cerebellopontine angle region | Tumor resection                | —                         | 1-y follow-up in the treatment |

CT=computed tomography; MRI=magnetic resonance imaging.

**Table 2**
Differential diagnoses of CPA lesions.

| Condition               | Differentiating signs/symptoms                                                                 | Differentiating tests                                                                 |
|------------------------|------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|
| Acoustic neuroma       | 1. The most common symptom is unilateral sensorineural hearing loss. 2. Signs include slower blink reflexes, poor balance, or nystagmus; however, these are relatively uncommon. 3. Large tumors can cause significant problems with increased intracranial pressure, gait disturbance, and co-ordination difficulties. | 1. MRI: uniformly enhanced, dense mass extending into internal acoustic meatus, absent dural tail. 2. CT imaging: internal acoustic meatus enlarged compared with other side on bone windows. |
| Meningioma             | Hearing loss is a less prominent symptom.                                                                 | 1. CT and MRI imaging findings show a large angle between the tumor and dura not centered over the internal acoustic meatus. Often has a dural tail. 2. Also, imaging displays bone hyperostosis, no internal acoustic meatus enlargement, and no or less extension into the internal acoustic meatus. |
| Epidermoid/cholesteatoma| Hearing loss is a less prominent symptom.                                                                 | MRI shows nonenhancing T1- and T2-weighted images.                                    |
| Facial nerve schwannoma| Facial weakness is prominent and occurs early. Sometimes associated with neurofibromatosis.                                                   | CT and MRI imaging results are similar to acoustic neuroma; however, enhancement extends into the geniculate ganglion of the facial nerve and facial canal. |
| Trigeminal schwannoma  | Clinically associated with more prominent facial numbness. Hearing loss is also less prominent. | 1. CT and MRI imaging displays a dumbbell-shaped mass over the petrous apex affecting Meckel cave. 2. The trigeminal nerve enhancement extends proximal to the tumor and does not extend into the internal acoustic meatus. |
| Hemangioblastoma        | May exhibit headache and hearing difficulty.                                                                 | About two-thirds of hemangioblastomas appear as well-circumscribed cystic masses with hypervascular mural nodules. Radiological findings of HMBs show multiple signal voids in the lesion, a peritumoral cyst, and peritumoral edema. |
| Lymphoma               | 1. The most common but atypical features include focal symptoms and intracranial hypertension. 2. Typical performance in Waldenström macroglobulinemia such as other organs infiltration and gammopathy are really rare. | CT and MRI imaging findings commonly show a homogeneous enhancing mass in the CPA, with relative iso-signal intensity on T1WI and T2WI. |

CPA=cerebellopontine angle; CT=computed tomography; MRI=magnetic resonance imaging; T1WI=T1-weighted imaging; T2WI=T2-weighted imaging.
mended.[20] No accurate prognostic data are available for primary CNS LPL because of the scarcity of case reports. LPL patients with no special treatment are reported to have a median survival of longer than 5 years; their 10-year survival rate is around 70% to 75%.[16,21] No deaths were reported among the 7 patients with follow-up data summarized in Table 1; their mean follow-up time was 18.9 months (range: 2.6–51 months).

3. Conclusion

We report here a rare case of LPL initially presenting with CPA compression. LPL rarely involves the CPA. It is difficult to diagnose pre-surgically and is usually misdiagnosed. With this article, we aimed to both present this rare entity and to emphasize the importance of keeping this differential diagnosis in mind when analyzing CPA lesions.

References

[1] Siasios I, Fotiadou A, Fotakopoulos G, et al. Primary diffuse large B-cell lymphoma of central nervous system: is still surgery an unorthodox treatment? J Clin Med Res 2015;7:1007–12.
[2] Naderi N, Yang DT. Lymphoplasmacytic lymphoma and Waldenstrom macroglobulinemia. Arch Pathol Lab Med 2013;137:580–5.
[3] Jauwal AK, Mahapatra AK, Sharma MC. Primary central nervous lymphoma presenting as bilateral cerebellopontine angle lesions: a rare case report. J Clin Neurosci 2004;11:328–31.
[4] Sugita Y, Muta H, Ohshima K, et al. Primary central nervous system lymphoma: a clinicopathological analysis of 3 cases, with emphasis on the differential diagnosis. Neuropathology 2016;36:314–23.
[5] Yamada S, Ishida Y, Matsuno A, et al. Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations. Leuk Lymphoma 2015;66:2141–5.
[6] Wen CY, Huang PH, Chang CJ, et al. Primary cerebellopontine angle lymphoma. Kaohsiung J Med Sci 2015;31:55–6.
[7] Briongos-Figueroa LS, Gomez-Traveso T, Perez-Castrillon JL. T-cell primary leptomeningeal lymphoma in cerebellopontine angle. BMJ Case Rep 2015;2015: pii: bcr2014208602.
[8] Chakraborty R, Gertz MA. Lymphoplasmacytic lymphoma: what we need to know. Leuk Lymphoma 2016;57:991–2.
[9] Guan J, Fang F, Shao Z. Lymphoplasmacytic lymphoma with IgA paraproteinemia. Clin Lab 2015;61:835–7.
[10] Sabattini E, Bacci F, Sagramoso C, et al. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica 2010;102:83–7.
[11] Sargent RL, Cook JR, Aguiler NL, et al. Fluorescence immunophenotypic and interphase cytogenetic characterization of nodal lymphoplasmacytic lymphoma. Am J Surg Pathol 2008;32:1643–53.
[12] Patkar N, Subramanian PG, Deshpande P, et al. MYD88 mutant lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia has distinct clinical and pathological features as compared to its mutation negative counterpart. Leuk Lymphoma 2015;56:420–5.
[13] Ikeda T, Harak, Yamanaka T, et al. A case of primary central nervous system malignant lymphoma developing from the optic chiasma and hypothalamus. Rinsho Shinkeigaku 2006;46:475–9.
[14] Beales E, Urbach H, Pels H, et al. Primary central nervous system immunocytoma: MRI and spectroscopy. Neuroradiology 2000;42:738–41.
[15] Lim T, Kim SJ, Kim K, et al. Primary CNS lymphoma other than DLBCL: a descriptive analysis of clinical features and treatment outcomes. Ann Hematol 2011;90:1391–8.
[16] Abbi KK, Muzaffar M, Gaudin D, et al. Primary CNS lymphoplasmytic lymphoma: a case report and review of literature. Hematol Oncol Stem Cell Ther 2013;6:76–8.
[17] Ta JH, Xu H. Cerebellopontine angle lymphoma. Otol Neurotol 2013;34:123–4.
[18] Shuangshoti S. Solitary primary lymphoma of the cerebellopontine angle: case report. Neurosurgery 1995;36:595–8.
[19] Chakraborty R, Kapoor P, Ansell SM, et al. Emerging therapeutic options for Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma. Expert Rev Anticancer Ther 2015;15:1143–56.
[20] Pileri SA, Zanazzi L, Sabattini E, et al. Lymphoplasmacytic lymphoma and marginal zone lymphoma: diagnostic challenges. Haematologica 2005;90:148.
[21] Cao X, Medeiros LJ, Xia Y, et al. Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression. Leuk Lymphoma 2015;6:27.